Signed a $15 billion deal with a Chinese partner for obesity and oncology drugs, positioning the company to tap into China's massive healthcare market and its cutting-edge research infrastructure.

A high-quality, well-managed company with a strong portfolio, but the investment case is a bet on management to meet an ambitious $80B revenue target by 2030, as the current pipeline seems unexciting.

Mentioned as a company that has made pricing deals under a proposed plan to enforce lower drug prices, indicating a potential headwind for revenue.

The company is reportedly planning a direct U.S. listing, which is viewed as a positive development that could potentially increase trading volume and visibility for U.S. investors.

The company's decision not to build new plants in the UK, opting for the US instead, is presented as a negative signal for UK's attractiveness for foreign investment, not a direct comment on the stock's performance.

Mentioned only as a partner of IonQ, using its quantum technology for drug discovery. No direct investment thesis was provided.

Mentioned as a partner in a successful project with IonQ and NVIDIA that resulted in a 20x speed-up for a drug discovery problem, showing its use of cutting-edge technology.

Included on a global watchlist of large-cap pharma companies to track the sector, with no specific buy or sell thesis mentioned.

Announced a $50 billion expansion of its U.S. manufacturing, which is seen as a bullish signal for the company's long-term strategy and resilience to potential tariffs.